ORIGINAL RESEARCH article
Volume 11 - 2020 | https://doi.org/10.3389/fneur.2020.00403
Clinical Characteristics of Anti-GABA-B Receptor Encephalitis
- 1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- 2China National Clinical Research Center for Neurological Diseases, Beijing, China
- 3Beijing Institute for Brain Disorders, Beijing, China
Objective: Anti-GABA-B (gamma aminobutyric acid-B) receptor encephalitis is an autoimmune disease mediated by GABA-B-related antibodies. To fully understand the disease, we collected clinical data from patients with GABA-B receptor encephalitis and conducted an analysis to draw conclusions.
Methods: All patients with GABA-B receptor encephalitis from the Neurology Department of Beijing Tiantan Hospital, affiliated with Capital Medical University, from August 2015 to September 2019 were accepted as study subjects. The clinical data of the patients were analyzed retrospectively and included the general demographic characteristics, clinical manifestations, and auxiliary examinations, including laboratory results, electroencephalograms (EEGs), brain magnetic resonance imaging (MRI), and positron emission tomography (PET-CT) results, as well as treatments.
Results: From August 2015 to September 2019, 14 cases of anti-GABA-B receptor encephalitis were diagnosed. Among these patients, middle-aged and elderly men were the main demographic, with an average age of 52 years; moreover, the onset of the disease was relatively sudden, and the time from onset to diagnosis was ~1 month. The main clinical symptoms were frequent epileptic seizures, cognitive dysfunction, and mental behavioral disorders. In seven (50%) patients, the leukocyte in cerebrospinal fluid (CSF) were increased. Five (36%) patients had elevated cerebrospinal fluid protein. In most patients, the oligoclonal bands (83%) of CSF were positive, and 24 h IgG levels (92%) were increased. Anti-Hu or anti-Yo antibodies were positive in two (14%) patients. Tumor markers in 10 (71%) patients indicated that neuron-specific enolase, gastrin-releasing precursor, non-small cell lung cancer-related antigen, or carcinoembryonic antigen levels were increased. EEG results often indicated slow waves, sharp waves, or spike waves in temporal areas. Brain MRI always showed high T2 signals in the medial temporal lobe, hippocampus, and amygdala and swelling in the medial temporal lobe and hippocampus. PET-CT scans almost showed abnormal metabolism in the hippocampus and temporal lobe. Three (21%) patients who underwent systemic PET-CT showed hypermetabolism in pulmonary parenchymal nodules and enlargement of mediastinal lymph nodes. All patients underwent high-dose hormone therapy or immunoglobulin immunotherapy. After treatment, the symptoms of epilepsy, cognitive disorders, and mental behavioral disorders improved to varying degrees. However, one patient died of lung cancer.
Conclusion: Anti-GABA-B receptor encephalitis mainly occurred in middle-aged and elderly men, and the disease onset was relatively sudden. Before disease onset, some patients experienced fever and non-specific respiratory symptoms, which mainly manifested as frequent epileptic seizures, cognitive dysfunction, and abnormal mental behavior. MRI and PET-CT revealed abnormal signals and local metabolism, respectively, in the temporal lobe. Moreover, the disease has a close relationship with lung cancer, which requires long-term follow-up observation.
Autoimmune encephalitis is a disease involving the limbic system and is mainly triggered by infection or autoimmune mechanisms. It can also have a relationship with neuro-antibodies that appear in response to cancer, such as those involved in paraneoplastic syndrome (1–4). In recent years, an increasing number of autoimmune encephalitis-related antibodies have been identified. Lancaster et al. reported anti-GABA-B (gamma aminobutyric acid-B) receptor encephalitis for the first time in 2010 (5). This disease is a type of autoimmune encephalitis mediated by GABA-B receptor antibodies and often involves the limbic system. Clinically, epilepsy, cognitive dysfunction, and mental behavioral abnormalities are the main manifestations, and epilepsy is often the first symptom (6). Recently, there has been an increasing number of reports on anti-GABA-B receptor encephalitis, which expands the understanding of this disease. For example, Ohta et al. reported a case of GABA-B encephalitis with multifocal hyperperfusion in the epithelia and subcortical MRI (7). Kitazaki et al. reported a case of GABA-B encephalitis with syncope (8). Yao et al. summarized seven, eight and 11 patients, respectively (9–11). The results showed that the clinical characteristics of anti-GABA-B encephalitis are intractable epilepsy, mental disorders, and cognitive dysfunction. Multiple antiepileptic drugs are important for the treatment of intractable epilepsy, and the disease is closely related to tumors. Lin et al. studied the risk of death and death-related factors in 28 patients with GABA-B encephalitis. The results showed that the 5-years mortality rate of patients with GABA-B encephalitis was high. Older age at disease onset, the presence of tumors, the number of complications, and deep vein thrombosis (DVT) are associated with death (12). To advance our understanding of this disease, in this study, we collected these cases for further analysis and summary.
Materials and Methods
In this study, we collected all patients with GABA-B receptor-related encephalitis in the Department of Neurology, Beijing Tiantan Hospital, affiliated with Capital Medical University, from August 2015 to September 2019. All patients were positive for the GABA-B antibody in the blood or cerebrospinal fluid (CSF). We analyzed their clinical characteristics, including general demographic characteristics (age and sex), present history, clinical manifestations (inducement, symptoms), past medical history, auxiliary examination characteristics (laboratory examination, electroencephalogram, electromyography, brain MRI, positron emission tomography), and treatment.
Laboratory tests included routine, biochemical, oligoclonal zone and 24 h IgG CSF tests; serum and CSF autoimmune assays for encephalitis-associated antibodies, such as GABA-B, glutamate decarboxylase 65 (GAD65), N-methyl-D-aspartate receptor (NMDAR), LGI1, contactin-associated protein-2 (CASPR2), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), antibodies, and paraneoplastic syndrome-associated antibodies, such as Ri, Hu, Yo, amphiphysin, CV2/CRMP5, paraneoplastic antigen MA2 (PNMA2) antibodies; assays for serum and CSF viral antibodies, such as IgG and IgM antibodies to rubella virus, measles virus, toxoplasma, cytomegalovirus, herpes simplex virus, Epstein-Barr (EB) virus, and coxsackie virus; autoantibody spectra including the anti-neutrophil cytoplasmic antibody, anti-nuclear antibody, anti-cardiolipin antibody, rheumatoid factor, anti-streptolysin O, and complement; thyroid function assays including total T3 (TT3), total T4 (TT4), free T3 (FT3), free T4 (FT4), thyroid-stimulating hormone (TSH), thyroglobulin (TG); assays for thyroid-related antibodies included anti-thyroglobulin antibody (TG Ab), anti-thyroperoxidase antibody (TPO Ab), thyrotropin receptor antibody (TRAb); and tests for tumor markers including cytokeratin 19 fragment (CYFRA21-1), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4), carbohydrate antigen 15-3 (CA15-3), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC), pro-gastrin-releasing peptide (ProGRP), and β-human chorionic gonadotropin (β-HCG).
Magnetic resonance imaging (MRI), with or without gadolinium injection, was performed using an NT 3.0-T Philips Gyroscan (Eindhoven, the Netherlands). A computed tomography (CT) scan was carried out using a Siemens Somatom Emotion CT machine (Erlangen, Germany). Ultrasonography was performed using a 3.5-MHz convex transducer (Toshiba SSA-250 A or Aloka SSD-630). 18F-FDG positron emission tomography (PET) images were acquired using a PET/CT scanner (Elite Discovery, GE HealthCare, Fairfield, Connecticut, USA).
We performed the analysis using SPSS 19.0. Descriptive statistics were used to analyze clinical data, such as the median and percentages.
General Demographic Characteristics
Among the 14 patients, nine were male, and five were female. The patients' ages ranged from 23 to 69, and their average age was 52. The onset of the disease was relatively sudden, with an average of 30 days (20 days to 2 years) elapsing from onset to diagnosis. Before the attack, three patients had a fever as high as 38.5°C. Another two patients had non-specific respiratory symptoms.
All patients (100%) had epilepsy, with frequent attacks occurring up to four to five times/day. Epilepsy could manifest in two main forms. The first form comprised paroxysmal limb stiffness convulsions, followed by loss of consciousness and limb convulsions, which could be accompanied by head and eye deflections to one direction or both eyes turning upwards, an askew angle of the mouth, spitting, clenched teeth, tongue biting, and urinary incontinence, lasting for several minutes and considered to be secondary tonic-clonic epilepsy. The second form comprised paroxysmal absence seizures, which exhibited similar symptoms, including stupefaction, swallowing, mouth twitching, head numbness, vomiting, and a purple face, and was considered what we called complex partial seizures. A third type comprised simple partial seizures, which manifested through paroxysmal tongue cramps, paroxysmal facial convulsions, or paroxysmal head deflection to one side, with both eyes turned upwards, clear senses, and relief after about 1 min. One patient experienced an initial simple partial attack, followed by a complex partial attack and then a secondary tonic-clonic attack. Two patients experienced an initial complex partial attack and then a secondary tonic-clonic attack. Three patients experienced complex partial attacks and secondary tonic-clonic attacks almost at the same time. Among these individuals, one patient in an epileptic persistent state showed non-convulsive status epilepticus, manifested as slow responses and irrelevant answers; after intravenous injection of diazepam, the symptoms improved.
Cognitive Function Impairments
11/14 patients had poor memory, especially related to decreased recent memory abilities and slow responses.
Mental Behavioral Abnormalities and Character Change
9/14 patients had mental behavioral abnormalities and character alterations. Mental behavioral abnormalities manifested as non-sensical and forced behaviors. Four patients slept more, whereas two were restless and did not sleep at night. Personality changes manifested as a loss of interest in things, a worsened temper, increased aggressive behaviors such as beating and scolding people, high emotional instability, and an increased tendency to become sad.
Other Clinical Characters
One patient walked unsteadily in the initial stage and another patient had difficulty understanding and expressing, she could only understand simple questions but replied with irrelevant answers (Table 1).
The lumbar puncture pressure was increased in 3/13 patients but was normal in other patients. In 7/14 patients, the leukocytes were increased in CSF. Furthermore, CSF protein was increased in 5/14 patients. All patients had normal CSF glucose and chloride levels. In 10/12 patients, the CSF oligoclonal zone (OB) was positive, and in 12/13 patients, the 24 h IgG level in CSF was increased.
Twelve patients were positive for GABA-B antibody in CSF and blood, and only two patients were positive for the GABA-B antibody in CSF. Other autoimmune encephalitis-related antibodies, including other neuron-specific antibodies in the blood and CSF (such as NMDA, CASPR2, AMPA1, AMPA2, LGI1, and GAD65 antibodies related to autoimmune encephalitis and Ri, Hu, Yo, amphiphysin, CV2/CRMP5, and PNMA2 antibodies related to paraneoplastic syndrome), were negative in 12 patients. Two patients were positive for paraneoplastic antibodies, one patient was slightly positive for anti-Yo antibody in blood, and one patient was positive for CSF and anti-Hu antibodies in blood and CSF.
Among the 14 patients, there were four with normal tumor markers, and the remaining 10 patients had different types of tumor markers that were increased to varying degrees, including six patients with increased NSE levels, four patients with increased serum gastrin-releasing peptide precursor (ProGRP) levels, three patients with increased non-small cell lung cancer-associated antigen (CYFRA21-1) levels, three patients with carcinoembryonic antigen (CEA) levels, one patient with increased CA19-9 levels, one patient with increased CA242 levels, one patient with increased CA72-4 levels, one patient with increased total prostate-specific antigen (t-PSA) levels, and one patient with elevated squamous cell carcinoma-associated antigen levels.
All (13/13) patients' IgM antibodies to virus (rubella virus, measles virus, toxoplasma, cytomegalovirus, herpes simplex virus, EB virus and coxsackie virus) either in CSF or in blood were negative. Cytomegalovirus IgG antibody was positive in CSF of 11/13 patients. All (13/13) patients had positive IgG antibodies to cytomegalovirus, herpes simplex virus, and EB virus in blood. Ten out of 13 patients were positive for rubella virus IgG antibody in blood.
All patients' autoantibody spectra were examined, including anti-neutrophil cytoplasmic antibody, anti-nuclear antibody, anti-cardiolipin antibody, rheumatoid factor, anti-streptolysin O, and complement. One patient was slightly positive for Scl-70, three were positive for Ro-52, one was positive for histone, and one was positive for gastric parietal cells. All patients were negative for rheumatoid factor, anti-O antibody and anti-neutrophil cytoplasmic antibody. All patients were examined for thyroid function: three patients were abnormal, and 11 were normal (Tables 2, 3).
Nine patients had sharp waves, spike waves, or slow waves in the temporal area, and six patients had sharp waves or slow waves in the frontal area in conjunction with abnormal waves in the temporal area (Figure 1; Table 4).
Figure 1. EEG of typical patients. (A) EEG showed that the slow wave of the low middle amplitude was seen continuously in the right anterior middle temporal area. (B) EEG showed slow waves in the bilateral frontotemporal area and spinous waves in the left posterior parietooccipital temporal area.
In one patient, the state of non-convulsive epilepsy was persistent, and the interval EEG was slow and fast in the bilateral frontal and anterior middle temporal areas, respectively. In the attack period, the patient's response was slow, the answer she provided did not correspond to what we asked, and the EEG showed slow wave, sharp wave, and fast rhythms in the bilateral frontal and anterior middle temporal areas. After an intravenous injection of diazepam, the patient's consciousness gradually became clear, and the EEG slow wave gradually disappeared at the same time (Figure 2).
Figure 2. EEG of a patient with status epilepticus. (A) During the attack, the patient's responses slowed, and the patient gave irrelevant answers. At the same time, the EEG results showed slow waves, sharp waves and fast rhythms in the bilateral frontal and anterior middle temporal areas. (B) After an intravenous injection of diazepam, the patient's consciousness gradually cleared, and the EEG slow wave gradually simultaneously disappeared.
In one patient, the MRI showed a long T2 signal shadow in the bilateral temporal, insular, and hippocampal slices, with the left side focus, fuzzy boundary, and uneven signals. The fluid-attenuated inversion recovery (FLAIR) scan showed a strong signal; the diffusion-weighted imaging (DWI) scan showed no diffusion limitation, and no obvious abnormal enhancement shadow was observed after injection. The temporal angle of the left lateral ventricle was enlarged (Figure 3). Seven patients showed abnormal signals in the temporal lobe and hippocampus (Figure 4). There were no specific MRI findings in six patients (Table 4).
Figure 3. Abnormal signals in bilateral temporal, insular and hippocampal regions indicated by brain MRI. MRI showed a long T2 signal in bilateral temporal, insular and hippocampal slices, with a fuzzy border and uneven signals on the left side. A FLAIR scan showed a strong signal, and no obvious abnormal enhancement was found after injection. The temporal angle of the left lateral ventricle was enlarged, and the midline remained in the middle. MRI, magnetic resonance imaging. (A) T1 (T1-weighted imaging). (B) T2 (T2-weighted imaging). (C) FLAIR (fluid-attenuated inversion recovery). (D) T1C (MRI enhanced scan).
Figure 4. Abnormal signals in the left temporal lobe, as indicated by brain MRI. MRI showed an oval mixed signal shadow in the left temporal cortex, a low signal in the FLAIR scan, a wide left fissure cistern, and no enhancement in the contrast-enhanced scan. MRI: magnetic resonance imaging. (A) T1 (T1-weighted imaging). (B) T2 (T2-weighted imaging). (C) FLAIR (fluid-attenuated inversion recovery). (D) T1C (MRI enhanced scan).
Figure 5. PET-CT of a typical patient. PET-CT suggested that the metabolism of the bilateral medial temporal lobe and hippocampus was increased, especially on the right side.
Figure 6. PET-CT of a typical patient. PET-CT suggested that the metabolism of the bilateral basal ganglia was increased, especially on the right side.
Tumor screening included abdominal ultrasound, thyroid ultrasound, breast and accessory ultrasound, urinary ultrasound, chest and abdominal computed tomography (CT), and whole-body PET-CT scans. In three patients, lung cancer was found by PET-CT (Table 4). Among them, one patient underwent bronchoscope lavage, and bronchial mucosa biopsy and pathology, which confirmed small cell lung cancer. Another patient underwent a lung biopsy and was pathologically diagnosed with small cell lung cancer too. But the other one refused a pathological biopsy.
Treatment and Follow-Up Study
Five patients underwent hormone shock therapy, three patients received gamma globulin therapy, and six patients received hormone shock and gamma globulin therapy. All patients were given antiepileptic medicines at the same time. After treatment, the number of epileptic seizures decreased, and mental and behavioral disorders and cognitive decline improved to varying degrees. After treatment, five patients were reexamined for GABA-B antibodies in blood and CSF. The titers of three patients' antibodies decreased, and those of two patients' antibodies became negative. Among the three patients with lung cancer indicated by PET-CT, two patients received radiotherapy and chemotherapy, one patient's tumor disappeared after treatment, however, one patient died. Another lung cancer patient refused radiotherapy or chemotherapy.
Autoimmune encephalitis (AE) generally refers to a kind of encephalitis mediated by autoimmune mechanisms that usually involve the limbic system. The main clinical manifestations are epilepsy, cognitive dysfunction, and abnormal mental behaviors (1, 2).
Since the discovery of anti-NMDAR encephalitis in 2007 (13), a series of autoantibodies against neuronal cell surfaces and synaptic proteins have been found, such as LGI1, GABAR, AMPAR, and CASPR2 antibodies (3, 14, 15). Anti-GABA-B receptor-related encephalitis is a type of rare AE that produces an immune response due to the production of GABA-B receptor-related antibodies.
There is evidence that disruption of the GABA-B-R structure and function can cause spontaneous seizures. Antibodies in the CSF of patients with anti-GABA-B receptor encephalitis can prevent the activation of the GABA-B receptor and block its function without changing the surface density of the receptor in vitro (6, 16). Anti-GABA-B receptor encephalitis mainly involves the limbic system and manifests as epilepsy, abnormal mental behavior and memory loss. The disease has a close relationship with small cell lung cancer, for which immunosuppressive therapy is effective, and rapid recognition of the disease is vital because it can improve the outcome of the tumor and nervous system (17).
Anti-GABA-B receptor encephalitis is rare, and the number of reported cases is low. To improve the understanding of this disease, all cases of anti-GABA-B receptor encephalitis in our department were collected, and the clinical data were summarized. According to the data from this group, anti-GABA-B receptor-related encephalitis mainly occurred in middle-aged and elderly men, and sometimes exhibited acute onset, fever, cold and other symptoms before the disease onset, which itself mainly manifested as epilepsy, cognitive function decline (especially recent memory decline), mental behavioral abnormalities and character changes, normal or increased lumbar puncture pressure. Almost half of the patients have elevated cerebrospinal fluid leukocytes. CSF protein can be normal or slightly elevated, and glucose and chloride levels are usually normal.
Patients' blood and CSF OB tests were often positive, and CSF 24 h IgG levels were increased. Blood tumor marker levels were often increased and cytosolic Hu or Yo antibodies in blood and CSF neurons could be positive. The MRI results of patients often indicated abnormal signals in the temporal lobe and hippocampus, and the PET-CT scan of the head often indicated abnormal metabolism of the temporal lobe and hippocampus. Three patients who received systemic PET-CT scans had malignant tumors, and two patients was pathologically diagnosed with small cell lung cancer.
After treatment, the number of epileptic seizures was reduced, and mental behavior and cognitive function were improved to varying degrees. After treatment, blood and cerebrospinal fluid were reexamined in five patients, shown that the titer of GABA-B antibody decreased or became negative.
A prominent feature of anti-GABA-B receptor encephalitis is a relatively rapid onset, with a fever that can occur before disease onset and in some cases, with non-specific respiratory symptoms (18). In our case, three people had fever as high as 38.5°C before the attack, and two people had non-specific respiratory symptoms. For patients with fever and non-specific respiratory symptoms, viral encephalitis caused by viral infection is not excluded. One of our patients had acute onset, fever before the onset of the disease, and a high body temperature of 38°C. This patient's symptoms included headache, epilepsy, slow response, and disordered hearing comprehension and language expression; in addition, this patient's CSF pressure was 280 mm H2O, the CSF white blood cells were increased, the CSF OB and 24 h IgG levels were increased too, and CSF ultrawide spectrum pathogenic microorganism detection revealed a low concentration of Mycoplasma pneumonia and human herpes simplex virus type 1. Brain MRI suggested that there were multiple patchy and slightly long T1 and slightly long T2 signal shadows in the bilateral frontal lobe, temporal lobe and insula. The FLAIR sequence showed a strong signal, DWI showed a high signal, and enhanced scanning showed linear enhancement in the bilateral frontal temporal pia mater. Considering that the patient suffered from viral encephalitis, antiviral treatment with acyclovir was given. The total number of cells and leukocytes decreased after lumbar puncture, but the CSF pressure remained high. In addition, GABA-B antibody and Yo antibody in blood and CSF were positive, but symptoms improved after gamma globulin and hormone shock treatment. Therefore, anti-GABA-B receptor encephalitis may have been secondary to viral infection, which should be classified as non-paraneoplastic-related anti-GABA-B receptor encephalitis (17).
In this group, all patients with GABA-B receptor encephalitis experienced epileptic episodes frequently, as many as 4–5 times/day, or even exhibited epileptic status. None of the patients achieved seizure-free status with antiepileptic drugs. One patient with a persistent epileptic state showed non-convulsive status epilepticus, manifested as delayed verbal response and incoherent speech. EEG showed that the fast rhythm in the bilateral frontal and anterior middle temporal areas changed: the amplitude gradually increased, the frequency gradually slowed, and the signal gradually spread to the next to the lead. After an intravenous injection of diazepam, the rhythm improved, indicating non-convulsive status epilepticus, and the symptoms improved significantly after hormone shock and gamma globulin treatment.
It is not surprising that patients with anti-GABA-B receptor encephalitis can show cerebellar ataxia because the GABA-B receptor is highly expressed in the cerebellum (17). Those with the disease can also show language comprehension and expression disorders, similar to those seen in NMDA receptor encephalitis, which may be related to the involvement of the temporal neocortex (19).
Anti-GABA-B receptor encephalitis can be accompanied by other autoantibodies, each with different clinical significance. These can include autoantibodies against Hu, NMDAR, voltage-gated calcium channel (VGCC), glutamic acid decarboxylase 65 (GAD65), and sex-determining region Y-box 1 (Sox1) as well as amphoteric antibodies (6, 11). In our case, one patient was positive for both CSF and serum anti-Hu antibodies, and the patients positive for anti-Hu antibodies had combined small cell lung cancer; thus, the presence of both GABA-B antibodies and Hu antibodies often points to potential lung cancer, which is similar to the results of previous reports (4, 17). Here, one patient was weakly positive for anti-Yo antibody, which is often related to female adnexa, breast and other tumors (20), but this patient had no tumor detected by adnexa or breast examination. There are few reports of anti-GABA-B receptor encephalitis combined with Yo antibody positivity, so we should continue to observe and expand the understanding of this disease in future research.
Anti-GABA-B receptor encephalitis mainly occurs in middle-aged and elderly men, and the onset of the disease is usually rapid. The main manifestations are frequent epileptic seizures, cognitive dysfunction, and abnormal mental behavior. The focus mainly involves the limbic system. Moreover, the disease is closely related to lung cancer, and long-term follow-up is needed. A comprehensive CSF test is of substantial significance for the treatment of new epileptic cases. A comprehensive understanding of the disease is a good way to prevent misdiagnosis and delayed treatment.
Data Availability Statement
All datasets generated for this study are included in the article/supplementary material.
The studies involving human participants were reviewed and approved by Beijing Tiantan Hospital Ethics Committee. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
FZ collected and analyzed the data and wrote this article. WS made a substantial contribution to the writing of the article and the production of the chart. RL and ZL collected some data. QW had full access to the data and takes responsibility for the integrity of the data and the accuracy of the analysis.
This work was supported by the National Key R&D Program of China (2017YFC1307500), Capital Healthy Development Research Funding (2016-1-2011), Beijing Postdoctoral Research Foundation (ZZ 2019-09), the Natural Foundation of Capital Medical University (PYZ2017132, PYZ2018074), the Beijing Key Laboratory on Clinical Study of Epilepsy (2016DXBL02), the Beijing Excellent Personnel Training Project (2016000021469G217), Epilepsy Research Funding of CAAE-UCB (2019034), and the Beijing Natural Science Foundation (7204256).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
AEDs, anti-epileptic drugs; GABA, gamma aminobutyric acid; EMG, electromyograms; EEG, electroencephalogram; MRI, magnetic resonance imaging; PET-CT, positron emission tomography/computed tomography.
1. Dutra LA, Abrantes F, Toso FF, Pedroso JL, Barsottini OGP, Hoftberger R. Autoimmune encephalitis: a review of diagnosis and treatment. Arq Neuropsiquiatr. (2018) 76:41–9. doi: 10.1590/0004-282x20170176
3. Seluk L, Taliansky A, Yonath H, Gilburd B, Amital H, Shoenfeld Y, et al. A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values. Clin Immunol. (2019) 199:29–36. doi: 10.1016/j.clim.2018.12.007
5. Lancaster E, Lai M, Peng XY, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. (2010) 9:67–76. doi: 10.1016/S1474-4422(09)70324-2
7. Ohta K, Seki M, Dalmau J, Shinohara Y. Perfusion IMP-SPECT shows reversible abnormalities in GABAB receptor antibody associated encephalitis with normal MRI. Brain Behav. (2011) 1:70–2. doi: 10.1002/brb3.14
8. Kitazaki Y, Ikawa M, Yamaguchi T, Enomoto S, Kishitani T, Shirafuji N, et al. Autoimmune encephalitis associated with anti-gamma-aminobutyric acid B receptor antibodies mimicking syncope: a case report. Intern Med. (2020) 59:843–7. doi: 10.2169/internalmedicine.3652-19
9. Lu Y, Wang Y, Wu XY, Jianhong W, Guoxing Z, Zhen H. Clinical features and long-term outcomes of seizures associated with autoimmune encephalitis: a follow-up study in East China. J Clin Neurosci. (2019) 68:73–9. doi: 10.1016/j.jocn.2019.07.049
10. Zeng W, Cao L, Zheng J, Yu L. Clinical characteristics and long-term follow-up of seven cases of anti-GABABR encephalitis in patients of han chinese descent. Neurol Sci. (2020) 41:373–8. doi: 10.1007/s10072-019-04095-9
12. Lin J, Li C, Li A, Liu X, Wang R, Chen C, et al. Encephalitis with antibodies against the gabab receptor: high mortality and risk factors. Front Neurol. (2019) 10:1030. doi: 10.3389/fneur.2019.01030
13. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. (2007) 61:25–36. doi: 10.1002/ana.21050
17. Guan HZ, Ren HT, Yang XZ, Lu Q, Peng B, Zhu YC, et al. Limbic encephalitis associated with anti-gamma-aminobutyric acid B receptor antibodies: a case series from China. Chin Med J (Engl). (2015) 128:3023–8. doi: 10.4103/0366-6999.168989
18. Hoftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. (2013) 81:1500–6. doi: 10.1212/WNL.0b013e3182a9585f
19. Constantinides VC, Kasselimis DS, Paraskevas GP, Zacharopoulou M, Andreadou E, Evangelopoulos ME, et al. Anti-NMDA receptor encephalitis presenting as isolated aphasia in an adult. Neurocase. (2018) 24:188–94. doi: 10.1080/13554794.2018.1524915
Keywords: anti-GABA-B receptor encephalitis, autoimmune encephalitis, clinical characteristics, positron emission tomography/computed tomography, electroencephalogram, magnetic resonance imaging, seizure
Citation: Zhu F, Shan W, Lv R, Li Z and Wang Q (2020) Clinical Characteristics of Anti-GABA-B Receptor Encephalitis. Front. Neurol. 11:403. doi: 10.3389/fneur.2020.00403
Received: 19 November 2019; Accepted: 17 April 2020;
Published: 21 May 2020.
Edited by:Fushun Wang, Nanjing University of Chinese Medicine, China
Reviewed by:Dinesh Upadhya, Manipal Academy of Higher Education, India
James Tao, University of Chicago, United States
Copyright © 2020 Zhu, Shan, Lv, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qun Wang, firstname.lastname@example.org